Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium (Nasdaq: COLL) reported strong 2025 results: product revenues $780.6M (+24% YoY) and record quarterly revenues of $205.4M (+13% YoY). Jornay PM reached $148.9M for FY 2025 (+48% YoY) and $45.9M in the quarter (+57% YoY). Adjusted EBITDA was $460.5M (+15% YoY). The company exited 2025 with $386.7M in cash and reaffirmed 2026 guidance: Product Revenues $805–825M; Jornay PM $190–200M; Adjusted EBITDA $455–475M.
Boston Legacy FC announced a multi-year partnership with Collegium Pharmaceutical (NASDAQ: COLL) to sponsor the Collegium Sensory Room. The rooms will be available at Gillette Stadium and Centreville Bank Stadium in 2026 and at White Stadium beginning in 2027.
The sensory rooms, designed with CHADD input, provide quieter, regulated spaces for fans with sensory sensitivities and include branded signage, digital mentions, and community programming.
Collegium (Nasdaq: COLL) will report fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET the same day. An audio webcast will be available on the Investors section of the company website and replayable approximately two hours after the event.
Collegium (Nasdaq: COLL) will present four real‑world data posters on its ADHD product Jornay PM at the APSARD Annual Conference, Jan 15–18, 2026, in San Diego.
Poster session: Jan 17, 2026, 11:45 a.m.–12:45 p.m. PT at Manchester Grand Hyatt, Seaport E. Posters (Nos. 73–76) cover dosing, comparative risks/benefits with Concerta, morning/evening functioning in youth, and depression/anxiety outcomes in adults.
Collegium (NASDAQ: COLL) provided 2026 financial guidance and a business update on Jan 8, 2026. The company expects product net revenues of $805M–$825M, Jornay PM net revenue of $190M–$200M, and adjusted EBITDA of $455M–$475M for full-year 2026. Collegium closed a $980M syndicated credit facility in December 2025, used in part to repay $581M of its prior term loan, yielding immediate annualized interest savings. The company also announced an authorized generic supply agreement with Hikma, with planned Nucynta ER AG launch in Q1 2026 and broader AG timing tied to third-party generics.
Collegium (Nasdaq: COLL) closed a five-year, $980 million inaugural syndicated credit facility maturing in 2030. The facility includes a $580M initial term loan, a $300M delayed draw term loan (undrawn at closing), and a $100M revolving credit facility (undrawn at closing).
Collegium used the initial term loan to repay approximately $581M of principal on its prior $646M term loan. Interest is set at SOFR plus 2.75%–3.75% based on first lien net leverage, with the closing rate at SOFR+2.75%. The company expects this refinancing to produce meaningful annualized interest savings and provide capital flexibility for general corporate purposes and business development. Truist Bank acted as administrative agent; a syndicate of banks served as arrangers and agents.
Collegium (Nasdaq: COLL) announced management will participate in three investor conferences in Nov–Dec 2025.
Jefferies London Healthcare Conference presentation: Nov 19, 2025 at 8:00 a.m. GMT in London; webcast available via the Investors section and replay archived for 90 days.
Piper Sandler 37th Annual Healthcare Conference fireside chat: Dec 2, 2025 at 2:30 p.m. ET in New York; webcast available via the Investors section and replay archived for 90 days.
Evercore Healthcare Conference: Dec 4, 2025 in Coral Gables, FL; details and webcasts available from the Investors section.
Collegium (Nasdaq: COLL) reported record Q3 2025 net revenue of $209.4M, up 31% year‑over‑year, and raised full‑year 2025 net revenue guidance to $775–$785M. The company posted Q3 adjusted EBITDA of $133.0M (up 27% YoY) and raised adjusted EBITDA guidance to $460–$470M. Jornay PM net revenue was $41.8M in Q3 with prescriptions up 20% YoY and 27,700 prescribers (up 22% YoY). The pain portfolio generated a record $167.6M in Q3. Collegium ended the quarter with $285.9M in cash, cash equivalents and marketable securities and generated $78.4M in operating cash flow.
Collegium Pharmaceutical (Nasdaq: COLL) announced a collaboration with entrepreneur and advocate Paris Hilton to share her personal ADHD journey and treatment experience on Oct 29, 2025.
The campaign aims to reduce stigma and encourage patients to talk with healthcare providers about treatment options. The release notes ADHD prevalence estimates of 15.5 million adults and 6.5 million children in the U.S., with ~70% of cases persisting into adulthood. Paris Hilton described being diagnosed as a young adult and choosing treatment with JORNAY PM (methylphenidate HCl) ER, a nighttime-dosed stimulant that starts on waking and lasts through the day.
Collegium Pharmaceutical (Nasdaq: COLL) announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company will host a live conference call and webcast at 8:00 a.m. ET following the release.
Conference call dial-in numbers are (877) 407-8037 (U.S.) and (201) 689-8037 (International) referencing the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio webcast and a replay will be available from the Investors section of the company website at www.collegiumpharma.com, with the replay posted about two hours after the event.